関連する実験動画
Updated: Sep 9, 2025

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.9K
急性不全性脳血管疾患 (TRACE II) でテネクテプラゼとアルテプラゼの有効性および安全性に対するフィブリノゲンの同様の効果
Lamia M'barek1,2, Aoming Jin1,2, Yuesong Pan1,2
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Journal of translational internal medicine
|September 2, 2025
まとめ
フィブリノゲンの濃度は,急性不全性脳卒中の治療において,テネクテプラスとアルテプラスの有効性や安全性に影響を与えない. この2つの薬は低フィブリノゲン濃度,正常濃度,高フィブリノゲン濃度で比較可能な結果を示しています.
科学分野:
- 神経科学
- 心血管医学
- 血液学
背景:
- 血液静止の重要な要因であるフィブリノゲンの濃度は,急性不全性脳卒中における静脈内血栓溶解 (IVT) の有効性に影響を与える可能性があります.
- 異なる血栓解消剤に対する異なるフィブリノゲン濃度の影響を理解することは,治療戦略を最適化するために極めて重要です.
研究 の 目的:
- 急性不全性脳卒中患者におけるテネクテプラスの有効性と安全性に対する血線維素濃度の影響を調査する.
- テネクテプラスとアルテプラスの治療結果にフィブリノゲン濃度が影響するかどうかを判断する.
主な方法:
- 多センター,前向き,ランダム化制御試験 (TRACE- II) で,4~5時間以内に治療された1409人の急性不全性脳卒中患者が参加した.
- 患者はテネクテプラスまたはアルテプラスを投与され,低 (< 2 g/ L),正常 (2 - 4 g/ L),および高 (> 4 g/ L) 血線維素濃度グループに分類された.
- 効果は,修正ランキンスコア (mRS 2- 6) で評価され,安全性アウトカムには,症状性頭蓋内出血 (symptomatic intracranial hemorrhage,sICH),パレンキマ性血腫 (parenchymal hematoma,PH2) と90日後の死亡率が含まれていた.
主要な成果:
- テネクテプラスとアルテプラスの治療効果は,すべてのフィブリノゲン濃度において一貫していた (相互作用P=0. 30).
- sICH,PH2,その他の出血事件を含む安全性結果は,フィブリノゲン濃度に関係なく,テネクテプラスとアルテプラスの間で比較可能であった (相互作用P値は0. 54から0. 94).
- 3ヶ月の死亡率は,異なるフィブリノゲン層における2つの治療法間で有意な違いを示さなかった (相互作用P=0. 58).
結論:
- 4. 5時間以内に治療された急性性不全性脳卒中の患者におけるテネクテプラスの有効性と安全性はアルテプラスと同等である.
- プラズマフィブリノゲン濃度は,テネクテプラスとアルテプラスの治療結果 (有効性および安全性) に有意な影響を与えないようです.
関連する概念動画
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Therapeutic Index
5.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.0K

